

Reference:	FOI.18514.25
Subject:	Breast cancer treatments
Date of Request:	6 October 2025

Requested:

- How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
 - Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
 - Abemaciclib + Fulvestrant
 - Alpelisib + Fulvestrant
 - Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only
 - Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel
 - Atezolizumab
 - Capivasertib
 - Capecitabine as a single agent
 - Carboplatin + Paclitaxel
 - Elacestrant
 - Eribulin as a single agent or in combination
 - Everolimus + Exemestane
 - Fulvestrant as a single agent
 - Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
 - Palbociclib + Fulvestrant
 - Parp Inhibitors (Olaparib/Talazoparib)
 - Pembrolizumab Monotherapy
 - Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide
 - Carboplatin + Paclitaxel + Pembrolizumab
 - Pertuzumab (Perteja) + Trastuzumab (Herceptin)
 - Phesgo (Pertuzumab + Trastuzumab in a single injection)
 - Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
 - Ribociclib + Fulvestrant
 - Sacituzumab Govitecan
 - Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
 - Trastuzumab deruxtecan (Enhertu)
 - Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel
 - Trastuzumab emtansine (Kadcyla)
 - Any other active systemic anti-cancer therapy
- In the past 3 months, how many patients have been treated with the following systemic anti-cancer therapies for breast cancer (please indicate whether they were treated for early or metastatic disease):

	Total Patients	Early Patients	Metastatic Patients
Phesgo (Pertuzumab + Trastuzumab in a single injection)			
Pertuzumab (Perteja) + Trastuzumab (Herceptin)			
Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel			

Trastuzumab deruxtecan (Enhertu)			
Trastuzumab emtansine (Kadcyla)			
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)			
Abemaciclib + Fulvestrant			
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)			
Ribociclib + Fulvestrant			
Capecitabine as a single agent			
Carboplatin + Paclitaxel			
Carboplatin + Paclitaxel + Pembrolizumab			

3. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

Our response

1. Hywel Dda University Health Board (UHB) provides within the table below, the number of patients that have been treated for breast cancer (any stage), with the listed Systemic Anti-Cancer Therapies (SACTs), during the period 1 July to 30 September 2025.

Please note:- some of the therapies listed are recorded together on the ChemoCare system and are unable to be split; therefore, the information has been provided as recorded on the ChemoCare system.

Anti-cancer therapy	Number
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	34
Abemaciclib + Fulvestrant	See above
Alpelisib + Fulvestrant	0
Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide	42
Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel	0
Atezolizumab	0
Capivasertib	0
Capecitabine as a single agent	23
Carboplatin + Paclitaxel	13
Elacestrant	*
Eribulin as a single agent or in combination	*
Everolimus only. (Exemestane not prescribed)	*
Fulvestrant as a single agent	22
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	36
Palbociclib + Fulvestrant	See above
Parp Inhibitors (Olaparib/Talazoparib)	*
Pembrolizumab	5
Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Pembrolizumab	*
Carboplatin + Paclitaxel + Pembrolizumab	11
Pertuzumab (Perteja) + Trastuzumab (Herceptin)	0
Phesgo (Pertuzumab + Trastuzumab in a single injection)	42

Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	34
Ribociclib + Fulvestrant	See above
Sacituzumab Govitecan	*
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	50
Trastuzumab deruxtecan (Enhertu)	30
Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	12
Trastuzumab emtansine (Kadcyla)	13
Any other active SACTs (Patients may have received more than one regimen)	20

Where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

2. The UHB has only treated breast cancer patients with one of the SACTs listed. Therefore, the UHB provides within the table below, the number of patients that have been treated with the SACTs, by stage, during the period 1 July to 30 September 2025.

SACT	Early	Metastatic
Phesgo (Pertuzumab + Trastuzumab in a single injection)	22	42

3. The UHB is currently participating in clinical trials for breast cancer and provides the names and numbers of patients partaking within the table below.

Name	Details	Number
Add Aspirin	Drug clinical trial: A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Status: recruitment ended, in follow-up.	36
ATNEC	Non-drug clinical trial: Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy. Status: open to recruitment.	6
MAMMO-50	Non-drug clinical trial: Mammographic surveillance in breast cancer patients aged 50 years and over: a randomised controlled trial. Status: recruitment ended, in follow-up.	235
POsitive Sentinel NOde (POSNOC)	Non-drug clinical trial: Adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy. A randomised controlled	*

	trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes. Status: recruitment ended, in follow-up.	
--	---	--